Childrens Gaucher Research Fund | a 501(c)(3) charitable organization ...
Childrens Gaucher. Site Search...
Read Childrensgaucher.org news digest here: view the latest Childrens Gaucher articles and content updates right away or get to their most visited pages. Childrensgaucher.org is not yet rated by Alexa and its traffic estimate is unavailable. We haven’t detected security issues or inappropriate content on Childrensgaucher.org and thus you can safely use it. Childrensgaucher.org is hosted with Unified Layer (United States) and its basic language is English.
Content verdict: Safe
Website availability: Live
Language: English
Last check:
-
N/A
Visitors daily -
N/A
Pageviews daily -
N/A
Google PR -
N/A
Alexa rank
Best pages on Childrensgaucher.org
-
Site Search Our 100% Commitment Our Financial Commitment — 100% of every dollar we receive goes to medical research. How do we do this? Combined Federal Campaign A Cure For Other Brain Diseases CGRF E...
-
Contact Us | Childrens Gaucher Research Fund
Our 100% Commitment Our Financial Commitment — 100% of every dollar we receive goes to medical research. How do we do this? Combined Federal Campaign A Cure For Other Brain Diseases CGRF Earns Seal of...
-
Importance of Research | Childrens Gaucher Research Fund
Importance of Research Gaucher Disease Type 2 and Type 3 are just two of more than 20 lysosomal diseases that affect the brain and lead to death. A cure for one disease may be a cure for all. Lysosoma...
Childrensgaucher.org news digest
-
7 years
Sanofi GenzymeFunds Important Research
Neuronopathic Gaucher disease (nGD) is a devastating disease that affects infants, and is caused by severe mutations in the GBA1 gene. GBA1 encodes an enzyme called glucocerebrosidase. The enzyme deficiency in GD results in the accumulation of the...
-
7 years
Sanofi GenzymePhase 2 Clinical Trial
Sanofi Genzyme’s Phase 2 Clinical Trial to Evaluate Oral Substrate Reduction Therapy for Gaucher Disease Type 3
Sanofi Genzyme is investigating an orally administered substrate reduction therapy in Gaucher disease type 3 as part of the 2-part LEAP clinical research study.... -
7 years
John BarrangerMemorial Research Grant
We thank Sanofi Genzyme for their selfless gesture to honor a good man and to give hope to families affected by Gaucher disease
In Grateful Memory of John A. Barranger, M.D., Ph.D., Sanofi Genzyme Corporation has established the “John Barranger Memorial Research Grant” that will fund $75,000 of medical research on neuronopathic Gaucher disease. Sanofi Genzyme has entrusted this... -
8 years
Call for ResearchMechanism of neuronopthic Gaucher disease
October 1, 2015
Limitation – United States Based Researcher/Institution
Amount – $75,000 to $100,000
Domain history
| Web host: | Unified Layer |
| Registrar: | Public Interest Registry |
| Registrant: | Children's Gaucher Research Fund |
| Updated: | February 05, 2020 |
| Expires: | May 14, 2025 |
| Created: | May 14, 1999 |
Whois record
Safety scores
Trustworthiness
GoodChild safety
N/A
